- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT01921998
Development of a Biomarker Directed Strategy to Ameliorate Common Toxicities From Conventional Chemotherapy (BioACT)
Side effects from chemotherapy can be severe in some patients leading to admission to hospital, a worse quality of life and delays in subsequent doses of chemotherapy. A blood test that could predict patients who will go on to develop severe side effects could be useful and might allow early intervention with medicines to reduce the severity of the symptoms and prevent admission to hospital.
This study will collect blood samples from patients with lymphoma or sarcoma who are receiving chemotherapy (with an expected admission rate for neutropenic sepsis, one of the side effects that most commonly results in hospital admission, of less than 20%). It will assess whether changes in blood proteins ("biomarkers") taken 2 days after the 1st chemotherapy can predict subsequent severe side effects throughout the 4 months of chemotherapy. In addition the investigators will collect data on quality of life and contact with medical professionals to assess the costs of chemotherapy toxicity to both the patient and health service. This will allow us in the future to model the cost effectiveness of using biomarkers in this manner to try and reduce chemotherapy toxicity.
Studienübersicht
Status
Intervention / Behandlung
Studientyp
Einschreibung (Voraussichtlich)
Kontakte und Standorte
Studienorte
-
-
-
Manchester, Vereinigtes Königreich, M20 4BX
- The Christie NHS Foundation Trust
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Beschreibung
Inclusion Criteria:
- Patients with lymphoma or sarcoma identified to receive out-patient chemotherapy with an anticipated febrile neutropenia rate of less than 20%. This would include 21 day R-CHOP in patients under 70 and single agent doxorubicin [Aapro et al, 2011a].
- Age 18 or older
- Performance Status 0-2
- Before patient registration, written informed consent must be given according to ICH/GCP, and national regulations.
Exclusion Criteria:
- Past history of HIV, Hepatitis B or C positive, due to the difficulties in handling high-risk specimens within CEP.
- Major surgery, radiotherapy, chemotherapy or mechanism based agents within the last 4 weeks.
- Radio-immunotherapy within the last 8 weeks.
- Bilirubin greater than 1.5 X the upper limit of normal and ALT greater than 2.5 x the upper limit of normal (as disturbed liver function tests are associated with elevated CK18) [Gonzalez-Quintela et al, 2009, Lavallard et al, 2011]
- Presence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
Kohorten und Interventionen
Gruppe / Kohorte |
Intervention / Behandlung |
---|---|
Biomarker and health economics
Biomarkers will be taken throughout cycle 1.
Health economics will be recorded using a patient side effect diary, a details of admission form, and a patient survey of healthcare use.
|
Biomarkers CK18 and FLT3 Ligand will be collected
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
sensitivity and specificity of changes in CK18 and FLT 3 ligand at day 3 of chemotherapy to predict subsequent severe toxicity
Zeitfenster: day 3
|
to confirm in a prospective cohort whether changes in CK18 and FLT3 ligand at day 3 of chemotherapy can identify patients at risk of subsequent severe chemotherapy toxicity
|
day 3
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
number of hospital admissions for febrile neutropenia
Zeitfenster: end of chemotherapy at approximately 6 months
|
end of chemotherapy at approximately 6 months
|
Total number of overnight stays or stays in A&E of over 4 hours spent in hospital
Zeitfenster: End of study chemotherapy at approximately 6 months
|
End of study chemotherapy at approximately 6 months
|
Dose intensity of chemotherapy achieved compared to planned cumulative dose on initiation of therapy
Zeitfenster: End of chemotherapy at approximately 6 months
|
End of chemotherapy at approximately 6 months
|
Number of total days delay in receiving chemotherapy treatment compared to planned delivery
Zeitfenster: end of chemotherapy at approximately 6 months
|
end of chemotherapy at approximately 6 months
|
Change in QOL at the start of cycles 2, 4 and 6 of chemotherapy and at the end of study as measured by functional assessment of cancer therapy general (FACT-G) and euroqol EQ-5D questionnaires
Zeitfenster: cycle 2 (week6), 4 (week 12), 6 (week 18) and end of study (approximately 6 months)
|
cycle 2 (week6), 4 (week 12), 6 (week 18) and end of study (approximately 6 months)
|
Total number of contacts (both face to face and telephone) with medical and nursing staff including visits to GP, Accident and Emergency, hospital clinics and telephone consultations with Hotline staff of hospital doctors
Zeitfenster: end of study chemotherapy at approximately 6 months
|
end of study chemotherapy at approximately 6 months
|
Mitarbeiter und Ermittler
Ermittler
- Studienstuhl: Alastair Greystoke, The Christie NHS Foundation Trust
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Voraussichtlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 11_DOG05_99
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Biomarker and health economics
-
VA Office of Research and DevelopmentTufts Medical CenterAbgeschlossen
-
Hacettepe UniversityAbgeschlossenTyp 2 DiabetesTruthahn
-
Massachusetts General HospitalTrefler FoundationRekrutierungKrebs | Brustkrebs | Kopf-Hals-Krebs | Schizophrenie | Lungenkrebs | Bipolare Störung | Magen-Darm-Krebs | Urogenitaler Krebs | Schwere schwere DepressionVereinigte Staaten
-
University of Illinois at ChicagoShirley Ryan AbilityLab; Oakland University; Access LivingAktiv, nicht rekrutierendBehinderte MenschenVereinigte Staaten
-
AIDS Arms Inc.AbgeschlossenHIV-1 | AIDSVereinigte Staaten
-
Emory UniversityAbgeschlossenFettleibigkeit | Autismus-Spektrum-StörungVereinigte Staaten
-
University of ReginaProvincial Health Services Authority; Saskatchewan Health Authority - Regina...Noch keine RekrutierungPsychische Gesundheit | Mukoviszidose bei Kindern | Geschwister | Internetbasierte InterventionKanada
-
Dr. Faizan AwanAbgeschlossenCovid19 | Beruflicher StressVereinigtes Königreich
-
University of ReginaProvincial Health Services Authority; Saskatchewan Health Authority - Regina...RekrutierungMukoviszidose | Psychische Gesundheit | Geschwister | Internetbasierte InterventionKanada
-
Johns Hopkins UniversityUniversity of Missouri-Columbia; Centers for Disease Control and PreventionAbgeschlossenGewalt in der PartnerschaftVereinigte Staaten